Publications

Watson AN, Shah SA, Shalhoub SD, Piedra KM, Komanduri KV, Kwon D, Pereira DL. Melphalan on day -1 versus day -2 in patients with plasma cell disorders undergoing autologous stem cell transplant. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 2022. PMID: 36245321

Thomas NJ, Brondfield S. Clinical progress note: Life-threatening side effects of targeted therapies for solid tumors. Journal of hospital medicine. 2022. PMID: 36239331

Singer L, Rugo HS. Little Downside. International journal of radiation oncology, biology, physics. 2022. PMID: 36244389

Atkinson TM, Lynch KA, Vera J, Olivares NM, Webb A, Diamond LC, Gonz?lez J, Lubetkin EI, Bucher G, Rosa-Cunha I, Berry-Lawhorn JM, Levine R, Aboulafia D, Schouten J, Holland SM, Cella D, Palefsky JM. Linguistic validation of the Spanish version of the Anal Cancer High-Grade squamous intraepithelial lesions outcomes Research Health-Related Symptom Index (A-HRSI): AMC-A04. Journal of patient-reported outcomes. 2022. PMID: 36219358

Rugo HS, Singer L. First, do no harm: risk of secondary cancer after breast cancer treatment. The Lancet. Oncology. 2022. PMID: 36240804

Rugo HS, Brufsky A, Liu X, Li B, McRoy L, Chen C, Layman RM, Cristofanilli M, Torres MA, Curigliano G, Finn RS, DeMichele A. Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2- metastatic breast cancer. NPJ breast cancer. 2022. PMID: 36220852

Pollock Y, Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik B, Olmos D, Lee JY, Uemura H, Bhaumik A, Londhe A, Rooney B, Brookman-May SD, De Porre P, Mundle SD, Small EJ. Clinical characteristics associated with falls in patients with non-metastatic castration-resistant prostate cancer treated with apalutamide. Prostate cancer and prostatic diseases. 2022. PMID: 36209239

Seufferlein T, Uhl W, Kornmann M, Alg?l H, Friess H, K?nig A, Ghadimi M, Gallmeier E, Bartsch DK, Lutz MP, Metzger R, Wille K, Gerdes B, Schimanski CC, Graupe F, Kunzmann V, Klein I, Geissler M, Staib L, Waldschmidt D, Bruns C, Wittel U, Fichtner-Feigl S, Daum S, Hinke A, Blome L, Tannapfel A, Kleger A, Berger AW, Kestler AMR, Schuhbaur JS, Perkhofer L, Tempero M, Reinacher-Schick AC, Ettrich TJ. Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)-a randomized phase II trial of the AIO pancreatic cancer group. Annals of oncology : official journal of the European Society for Medical Oncology. 2022. PMID: 36209981

Sakafu LL, Philipo GS, Malichewe CV, Fundikira LS, Lwakatare FA, Van Loon K, Mushi BP, DeBoer RJ, Bialous SA, Lee AY. Delayed diagnostic evaluation of symptomatic breast cancer in sub-Saharan Africa: A qualitative study of Tanzanian women. PloS one. 2022. PMID: 36201503

Loeser AL, Gao L, Bardia A, Burkard ME, Kalinsky KM, Peppercorn J, Rugo HS, Carlson M, Cowden J, Glenn L, Maues J, McGlown S, Ni A, Padron N, Lustberg M. Patient-centered dosing: oncologists' perspectives about treatment-related side effects and individualized dosing for patients with metastatic breast cancer (MBC). Breast cancer research and treatment. 2022. PMID: 36198984

Kim JW, Luck C, Wu W, Ponce RK, Lin YK, Gupta N, Okimoto RA. Capicua suppresses YAP1 to limit tumorigenesis and maintain drug sensitivity in human cancer. Cell reports. 2022. PMID: 36198276

Ossowski S, Neeman E, Borden C, Stram D, Giraldo L, Kotak D, Thomas S, Suga JM, Lin A, Liu R. Improving Time to Molecular Testing Results in Patients With Newly Diagnosed, Metastatic Non-Small-Cell Lung Cancer. JCO oncology practice. 2022. PMID: 36191286

Sanft T, Day A, Peterson L, Rodriguez MA, Ansbaugh S, Armenian S, Baker KS, Ballinger T, Broderick G, Demark-Wahnefried W, Dickinson K, Fairman NP, Friedman DL, Goldman M, Henry NL, Hill-Kayser C, Hudson M, Khakpour N, Koura D, McDonough AL, Melisko M, Mooney K, Moore HCF, Moryl N, Neuman H, O'Connor T, Overholser L, Paskett ED, Patel C, Pirl W, Porpiglia A, Ruddy KJ, Schapira L, Shockney L, Smith S, Syrjala KL, Tevaarwerk A, Yang EH, Zee P, McMillian NR, Freedman-Cass DA. NCCN Guidelines� Insights: Survivorship, Version 1.2022. Journal of the National Comprehensive Cancer Network : JNCCN. 2022. PMID: 36240847

Kelley RK. The Evolving Role of Combination Systemic Therapies in Hepatocellular Carcinoma. Gastroenterology & hepatology. 2022. PMID: 36397929

Tempero M. We Are Winning This War! Journal of the National Comprehensive Cancer Network : JNCCN. 2022. PMID: 36240853

Benson AB, Venook AP, Al-Hawary MM, Azad N, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Garrido-Laguna I, Grem JL, Gunn A, Hecht JR, Hoffe S, Hubbard J, Hunt S, Jeck W, Johung KL, Kirilcuk N, Krishnamurthi S, Maratt JK, Messersmith WA, Meyerhardt J, Miller ED, Mulcahy MF, Nurkin S, Overman MJ, Parikh A, Patel H, Pedersen K, Saltz L, Schneider C, Shibata D, Skibber JM, Sofocleous CT, Stotsky-Himelfarb E, Tavakkoli A, Willett CG, Gregory K, Gurski L. Rectal Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : JNCCN. 2022. PMID: 36240850

Christina Phuong, Amy M. Lin, Izzy Friesner, Lisa Ni, Rahul Raj Aggarwal, Hala Borno, Vadim S Koshkin, Arpita Desai, Terence W. Friedlander, Lawrence Fong, Rohit Bose, Jonathan Chou, Tammy J. Rodvelt, Osama Mohamad, Anthony C. Wong, Felix Y Feng, Eric Jay Small, Julian C. Hong. Reliability of real-world data for diagnosis of metastatic prostate cancer. Journal of Clinical Oncology. 2022. PMID:

Rubenstein JL. Primary CNS Lymphoma: Progress With Dose-Intensive Consolidation. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2022. PMID: 36179277

Allen GM, Lim WA. Rethinking cancer targeting strategies in the era of smart cell therapeutics. Nature reviews. Cancer. 2022. PMID: 36175644

Aggarwal R, Alumkal JJ, Szmulewitz RZ, Higano CS, Bryce AH, Lopez-Gitlitz A, McCarthy SA, Miladinovic B, McQuarrie K, Thomas S, Zhang K, Small EJ. Randomized, Open-Label Phase 2 Study of Apalutamide plus Androgen Deprivation Therapy versus Apalutamide Monotherapy versus Androgen Deprivation Monotherapy in Patients with Biochemically Recurrent Prostate Cancer. Prostate cancer. 2022. PMID: 36212187